Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Non-Small-Cell Lung 20Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Lung Neoplasms 14Mouth Neoplasms 10Laryngeal Neoplasms 10Carcinoma 10Urinary Bladder Neoplasms 8Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 6Mesothelioma, Malignant 6Medulloblastoma 6Gallbladder Neoplasms 6Neuroblastoma 5Ganglioneuroblastoma 5Fallopian Tube Neoplasms 5Lymphoid Interstitial Pneumonia 4Vulvar Neoplasms 3Urethral Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Carcinoma, Transitional Cell 3Brenner Tumor 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infiltrating Bladder Urothelial Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡